BioScience Ventures Group AG
BioScience Ventures Group AG is a venture capital firm based in Munich, Germany, that specializes in seed and early-stage investments in the life sciences sector. Focusing primarily on pharmaceuticals, biotechnology, medical technology, and medical devices, the firm targets companies located in Germany, Austria, and Switzerland. BioScience Ventures Group typically invests between €0.2 million and €0.5 million in each investment round and prefers to take a board seat in its portfolio companies. Established in 2001, the firm is composed of a team of experienced business angels with backgrounds in medicine and pharmacology, which equips them to support drug development and the design of preclinical and clinical studies, particularly in the area of biologics, such as antibodies and proteins.
Nano4Imaging GmbH, founded in 2011 and based in Aachen, Germany, specializes in the development and production of contrast agents and medical devices that enhance in-vivo imaging for implants, transplants, and minimally invasive devices like catheters and guidewires. The company offers a range of products including MRWire EmeryGlide, a magnetic resonance imaging (MRI) conditional guidewire, and various coatings such as MagnaFy-MRI for MRI visibility and MagnaFy-CT for computed tomography (CT) and X-ray visibility. These innovations facilitate precise navigation for medical interventions, particularly in treating cardiovascular diseases and enhancing radiotherapy. By leveraging nanotechnology, Nano4Imaging aims to improve the accuracy of diagnostic imaging, allowing healthcare professionals to monitor the functionality of medical devices effectively.
MagnaMedics engineers and produces magnetic nano- and microparticles that are used in medical devices, drug delivery tools and diagnostic kits. Diagnostic kits are used for determination of biomarkers in body fluids; the company focuses on proteomics and more specifically on high-quantity isolation of proteins as well as on research customers active in high-throughput screening of biomarkers.
Apeptico Forschung und Entwicklung GmbH is a biotechnology company based in Vienna, Austria, specializing in the development and marketing of peptide-based therapeutic drugs aimed at treating chronic and life-threatening diseases. Founded in 2008, the company offers a portfolio of products under the brand PEPBASE, focusing on innovative medicinal solutions. Apeptico's approach emphasizes the use of synthetically produced peptide structures, which helps mitigate the risks commonly associated with gene and cell technologies. This strategy not only enhances treatment efficacy but also aims to lower overall treatment costs and streamline the therapy process for healthcare providers.
Diaferon
Seed Round in 2007
Diaferon GmbH is a biotechnology company. Diaferon GmbH is based in Munich, Germany.
ugichem is an innovative biotech company based on unique chemistry and focused on the development of novel antisense drugs. Their mission is to turn antisense into therapeutics.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.